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Background: Dystonia is a movement disorder characterized by involuntary sustained muscle contractions causing
twisting and repetitive movements or abnormal postures. Some cases of primary and neurodegenerative dystonia
have been associated with mutations in individual genes critical to the G1-S checkpoint pathway (THAP1, ATM, CIZ1
and TAF1). Secondary dystonia is also a relatively common clinical sign in many neurogenetic disorders. However,
the contribution of structural variation in the genome to the etiopathogenesis of dystonia remains largely
unexplored.
Case presentation: Cytogenetic analyses with the Affymetrix Genome-Wide Human SNP Array 6.0 identified a
chromosome 13q34 duplication in a 36 year-old female with global developmental delay, facial dysmorphism, tall
stature, breast cancer and dystonia, and her neurologically-normal father. Dystonia improved with bilateral globus
pallidus interna (GPi) deep brain stimulation (DBS). Genomic breakpoint analysis, quantitative PCR (qPCR) and
leukocyte gene expression were used to characterize the structural variant. The 218,345 bp duplication was found
to include ADPRHL1, DCUN1D2, and TMCO3, and a 69 bp fragment from a long terminal repeat (LTR) located within
Intron 3 of TFDP1. The 3' breakpoint was located within Exon 1 of a TFDP1 long non-coding RNA (NR_026580.1). In
the affected subject and her father, gene expression was higher for all three genes located within the duplication.
However, in comparison to her father, mother and neurologically-normal controls, the affected subject also showed
marked overexpression (2×) of the transcription factor TFDP1 (NM_007111.4). Whole-exome sequencing identified
an SGCE variant (c.1295G > A, p.Ser432His) that could possibly have contributed to the development of dystonia in
the proband. No pathogenic mutations were identified in BRCA1 or BRCA2.
Conclusion: Overexpression of TFDP1 has been associated with breast cancer and may also be linked to the tall
stature, dysmorphism and dystonia seen in our patient.
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Chromosome 13q34 amplifications have been reported in
lung cancer [1], small bowel adenocarcinoma [2], hepato-
cellular carcinoma [3], squamous cell carcinoma of the
esophagus [4], and breast cancer [5,6]. Overexpression of
genes in this region, particularly TFDP1, may be causally
associated with the development or progression of these
malignancies [5,6]. TFDP1 encodes the transcription
factor DP-1. DP-1 forms heterodimers with E2F family
members to enhance their DNA-binding and promote
transcription of E2F target genes. The E2F/DP-1 complex
plays a critical role in the G1-S cell-cycle transition [7].
Numerous stimuli, including DNA damage, TGFβ, repli-
cative senescence, and contact inhibition, exert control
over the G1-S checkpoint pathway [8,9]. Defects in this
pathway have been associated with developmental defects,
neurodegenerative disorders, cancer and dystonia [10-12].
In particular, five genes linked to dystonia appear to be
involved upstream or downstream of DP-1 in the G1-S
checkpoint pathway (ATM, CIZ1, TOR1A, THAP1 and
TAF1). Autosomal recessive mutations of ATM increase
risk for malignancies and typically present as ataxia tel-
angiectasia. However, some patients present with isolated
dystonia [11]. Moreover, female carriers are at higher
risk for breast cancer [13]. The encoded protein, ataxia
telangiectasia mutated (ATM), activates p53 by phosphor-
ylating the ubiquitin E3 ligase MDM2 [14]. Reduced
neuronal expression of TAF1 is linked to a form of
dystonia-parkinsonism known as Lubag or DYT3 [15].
TAF1 mediates degradation of p53 via phosphorylation
at Thr-55 [16]. CIZ1 interacts with p21Cip1 [17]. TorsinA,
the protein encoded by TOR1A, interferes with TGFβ
signaling pathway [18]. Finally, the S-phase gene RRM1 is
a direct transcriptional target of THAP1 [19].
Herein, we report a unique patient with a chromosome
13q34 duplication, dystonia, dysmorphism, intellectual
disability, psychosis, tall stature, and breast cancer. Gene
expression studies suggest that one or more of these
phenotypic features may be due to overexpression of
TFDP1.
Case presentation
A 36 year-old right-handed Hispanic woman presented
for evaluation of stiffness, painful muscle spasms, diffi-
culty walking, falling, and abnormal involuntary hyper-
kinetic movements that had progressed over three years.
She also reported decreased motivation, speech articula-
tion problems, and difficulty with all activities of daily
living as well as with handwriting. The chronology of
proband’s signs and symptoms is outlined in Table 1.
She was born by cesarean section and was noted to
be hypoxemic but was delivered at full term. She was
the fourth child in her family, and none of the other
children had neurological disorders or cancer relatedillnesses. Her motor and cognitive development was
delayed. She did not sit until after 6 months of age and
did not walk until 18 months of age, and was enrolled
in special education classes in the first grade.
Because of her tall stature at 7 years of age, a diagnosis
of Marfan syndrome was suggested by her physicians
but never confirmed with molecular genetic testing. She
completed a total of 6 years of schooling. At 30 years of
age, she developed a psychiatric disturbance with psych-
otic features. She became obsessed with popular rock
and roll bands and experienced visual and auditory
hallucinations. She was briefly hospitalized for psychosis,
and was treated successfully for three years with ris-
peridone (1 mg three times daily), valproic acid and
buproprion. However, she then began to manifest what
was described as choreoathetotic and dystonic movements
in her left arm along with blepharospasm. She was
treated with levetiracetam, carbamazepine, oxcarbama-
zepine, clonazepam, biperidone, haldoperidol, aripiprazole,
topiramate, baclofen, carbidopa/levodopa, chlorpromaz-
ine, amantadine, trihexyphenidyl, and botulinum toxin
injections. These medical treatments were only mildly
beneficial, and her neurological condition progressively
worsened with the appearance of hyperkinetic movements
affecting her right arm and trunk.
At age 35, she was diagnosed with breast cancer dur-
ing a routine physical examination. She underwent a
radical right mastectomy with preservation of the areola
and nipple. Serum prolactin levels were not obtained.
She was treated with tamoxifen, post-operatively, and
has shown no evidence of local recurrence or metastasis
of her breast cancer. Pathology revealed an encapsulated
mucinous carcinoma, grade I. The tumor cells inside
mucous lakes expressed estrogen and progesterone re-
ceptors and did not over-express Her2/neu.
Her hyperkinetic movement disorder showed an initial
modest response to tetrabenazine. However, dystonia
gradually worsened with painful retrocollis and truncal
dystonia. Over a period of 6 months, she lost 25 pounds
and became profoundly debilitated by dystonia, spending
most of her waking day lying face down.
Brain magnetic resonance image (MRI) was unremark-
able and routine laboratory testing including a compre-
hensive metabolic profile was normal. A 24-hour urine
copper for Wilson’s disease was also normal. A 99mTc-
HMPAO single photon emission computed tomography
(SPECT) showed asymmetric and decreased radiotracer
uptake in basal ganglia regions including the caudate,
putamen, and globus pallidus. Molecular cytogenetic
analysis exposed a chromosome 13q34 duplication.
At age 36, general physical examination revealed facial
dysmorphism with hypertelorism, down slanting palpe-
bral fissures, mild ptosis and large low-set ears with mild
posterior rotation (Figure 1). Other clinical features
Table 1 Chronology of proband’s signs and symptoms
1976 Born by cesarean section at full term.
1976-1986 Did not sit until after 6 months of age and did not walk until 18 months of age.
Enrolled in special education classes in the first grade.
Developmental delay, Marfanoid features, dysmorphic features, strabismus, mitral valve prolapse were described by pediatrician.
2003-2007 Appearance of psychiatric symptoms including psychosis treated with valproic acid, risperidone and buproprion.
2008 Movement disorder becomes manifest (choreoathetotic and dystonic movements in the left arm along with
blepharospasm) and is treated with levetiracetam, carbamazepine, oxcarbazepine, lorazepam, biperiden, haloperidol,
aripiprazole, topiramate, chlorpromazine, carbidopa/levodopa, baclofen, amantadine, trihexyphenidyl, botulinum toxin
injections, and tetrabenazine.
2009 Despite medical treatment and discontinuation of dopamine blocking drugs, neurological condition progressively worsens
with hyperkinetic movements appearing in the right arm and trunk.
2010 Mucinous carcinoma of the right breast diagnosed and treated with a modified radical mastectomy with skin preservation
and immediate reconstruction with breast prosthesis.
Histology report shows no residual tumor at tissue margins and lymph nodes free of tumor.
Post-operative treatment with tamoxifen.
Worsening of the dystonia with appearance of truncal dystonia including painful retrocollis.
Difficulty staying upright for even short periods.
Weight loss of 25 pounds.
2011 Implantation of bilateral globus pallidus internus electrodes for deep brain stimulation.
Marked improvement of dystonia 4 months after surgery.
Subject able to feed herself, sit upright and walk.
Significant improvements in neck pain.
Revision of left and right pulse generators, and replacement of left extension cable after lead fracture due to twiddler
syndrome (obsessively moving the generators in the chest leading to device fracture).
2013 Facial dystonia markedly improved. Sustained control of dystonia with deep brain stimulation.
Moscovich et al. BMC Medical Genetics 2013, 14:70 Page 3 of 9
http://www.biomedcentral.com/1471-2350/14/70included hirsutism, low anterior hairline, micrognathia,
brevicollis, scoliosis, arachnodactyly, tall stature (182.9 cm),
and a weight of 62.3 kg (body mass index = 18.6). On
neurological examination, she was moderately inattentive.
No primitive reflexes were noted. She scored a 19/30 on
the Montreal Cognitive Assessment (MoCA). MoCA
scores of 26 and higher are considered normal. Although
cranial nerves were all normal, speech was mildly
dysarthric, and facial dystonia was overt. Muscle strength
testing was normal. There was no focal atrophy or fascic-
ulations. There was no obvious upper extremity ataxia
although testing of coordination was limited by the
presence of dystonia. Gait was broad-based and ataxic,
and she required assistance to walk. Walking was also
compromised by dystonic posturing of her trunk and
arms. Sensory testing was normal. Cervical dystonia
was manifest as severe retrocollis. Truncal and bilateral
arm dystonia had a clear action component and wors-
ened during movement, particularly walking. No contrac-
tures were present in the arms or legs. A score of 37
was recorded for the pre-operative Unified Dystonia
Rating Scale (UDRS, maximum score is 112).
The proband underwent bilateral globus pallidus in-
ternus (GPi) deep brain stimulation (DBS). She gradually
improved and after 4 months her facial dystonia wasmarkedly better and she became able to feed herself. She
could sit upright and tolerated sitting for progressively
longer periods of time. Both subjective and objective
improvements in postural stability, gait, and retrocollis
were noted. Neck pain and upper limb dystonia were
significantly improved. The 4-month post-operative
score on the UDRS was 23. However, shortly after this
period of clinical improvement, she experienced hardware
malfunction due to lead wire fractures caused by her
twiddling the implantable pulse generators (IPGs). The
lead connectors were replaced and the IPGs tacked
down to prevent twiddling, and her dystonia improved
once again. Her outpatient clinical course has been
compromised by dysphagia and hospitalizations for
treatment of aspiration pneumonia which ultimately
required placement of a percutaneous endoscopic gas-
trostomy (PEG) tube.
The proband’s parents and two brothers were neuro-
logically normal and showed no dysmorphic features.
Her mother and father were 167.6 and 170.2 cm tall, re-
spectively. There was no history of dystonia or breast
cancer in any first or second degree relative.
All human studies were performed in accordance with
institutional review board guidelines and the Helsinki
Declaration. Written informed consent for genetic studies
Figure 1 Frontal (A) and lateral (B) photographs 4 months after
GPi DBS show the presence of mild facial dystonia and
dysmorphic features. C) Arachnodactyl and hirsutism. D) Virtual
resolution of facial dystonia 2 yrs after GPi DBS.
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patient, her parents and neurologically-normal controls.
All genetic analyses were approved by the University of
Tennessee Health Science Center Institutional Review
Board (#01-07346-XP). The proband and her parents were
examined at the Center for Movement Disorders and
Neurorestoration, Department of Neurology, University
of Florida, and were part of the IRB approved INFORM
clinical database. The proband’s siblings live outside the
United States and were unable to complete a study visit at
the University of Florida. However, the siblings were
interviewed via Skype (www.skype.com). Recruitment
of neurologically-normal controls has been described
previously [20].Identification of the duplication
Clinical cytogenetic analyses were performed by Quest
Diagnostics (Madison, NJ, USA) on DNA derived from
whole blood using the Affymetrix Genome-Wide Human
SNP Array 6.0. The Affymetrix 6.0 microarray contains
over 1.8 million probes, including 900,000 copy number
probes and 900,000 SNP probes. The average inter-probe
distance is 700 base pairs. Thresholds for genome-widescreening were set at >200 kb for gains, >50 kb for losses
and 10 Mb for segments of homozygosity. A ~225 kb gain
of unclear clinical significance was detected in the pro-
band at 13q34. Four genes were involved in the genomic
alteration: ADPRHL1, DCUN1D2, TMCO3 and TFDP1.
Follow-up analyses of the parents using the same array
indicated that the variant was of paternal origin. The
classic TOR1A ΔGAG mutation was excluded with Sanger
sequencing.
For genomic breakpoint analysis and confirmation of
copy numbers, DNA was extracted from peripheral
blood leucocytes using Roche’s DNA Isolation Kit for
Mammalian Blood (Indianapolis, IN, USA). DNA quantity
and quality were analyzed with a NanoDrop ND-1000
spectrophotometer (Wilmington, DE, USA) and agarose
gel electrophoresis. Quantitative PCR (qPCR) primers and
probes were designed via Roche’s Universal Probe Library
to encompass the estimated boundary regions (Additional
file 1). qPCR was performed using 20 ng of template DNA
and 200 nM of each primer in a 10-μl reaction volume
with the LightCycler™ 480 system and Universal TaqmanW
probes (Roche). The following cycling conditions were
employed: 95°C for 5 min; 45 cycles at 95°C for 10 s,
60°C for 30 s, and 72°C for 12 s. Copy numbers were
referenced to an endogenous control (RPPH1) and 9
neurologically-normal unrelated subjects. All assays were
done in triplicate and means were used for comparisons.
Long-range PCR was then performed using primers
outside the boundary regions of the duplication (for
example, Dup237_p13F and Dup025_p23R in Additional
file 1). After agarose gel purification, PCR products
were sequenced in the forward and reverse directions
on an Applied Biosystems 3130XL Genetic Analyzer
(Carlsbad, CA, USA).
Relative quantitative reverse-transcriptase PCR (QRT-
PCR) was done to analyze the expression levels of genes
located within or near the structural variant. In brief,
Ambion’s LeukoLOCK™ Total RNA Isolation System and
TRI ReagentW were used to isolate RNA from peripheral
blood leukocytes. Leukocyte RNA was not available for
the proband’s siblings. Reverse transcription was per-
formed with Ambion's RETROscript™ kit using 500 ng
total RNA as template along with random oligonucleotide
primers. The reaction mixtures were incubated at 44°C for
1 hr and then at 92°C for 10 min. QRT-PCR was
performed using the LightCyclerTM 480 system with gene
specific primers (Additional file 1) and Universal TaqmanW
probes (Roche) for 4 genes involved in the duplication
region (ADPRHL1, DCUN1D2, TMCO3, and TFDP1),
TFDP1 long non-coding RNA (lncRNA), 1 gene near
the duplication (GRTP1), and the endogenous control
(PPID), which encodes 40 kDa peptidyl-prolyl cis-trans
isomerase D (cyclophilin D). All assays were performed
in triplicate and means were used for comparisons.
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mapping flanking SNPs and Affymetrix copy number
(CN) probes for the 13q34 duplication in both the
proband and her father (bolded were predicted by Quest
Diagnostics to be within the gain): SNP_A-1803536




07), CN_091834(Chr13:114249942), CN_636300 (Chr13:
114257699), and SNP_A-2105146(Chr13:114257910). With
qPCR of genomic DNA we were able to confirm duplica-
tion of ADPRHL1, DCUN1D2, and TMCO3, and showed
that GRTP1 and TFDP1 were, in fact, outside the dupli-
cated segment (Figure 2 and Table 2). Fold changes of
approximately 1.5× for ADPRHL1, DCUN1D2 and
TMCO3 were consistent with a duplication involving
one allele of each gene. Stepwise long-range PCR and
Sanger sequencing allowed us to identify the 5′ and 3′
breakpoints (Chr13:114,020,670 and Chr13:114,239,014)
in the affected subject and her father (Figure 2). The
duplicated segments were separated by a 69 bp frag-
ment. Nucleotide query with Basic Local Alignment
Search Tool (BLAST) suggested that this 69 bp fragment
(Chr13:114,275,816-884) was duplicated from Intron 3
of TFDP1, 36 kb 3′ to its location between the larger
duplicated segment. A single deoxyadenosine (A) was
detected 5′ to the smaller 69 bp fragment. The 5′
breakpoint (Chr13:114,020,670) was located 3′ to the
end of GRTP1 (Chr13:114,018,463) and the 3′ breakpoint
(Chr13:114,239,014) was located 5′ to the start of TFDP1
(NM_007111.4: Chr13:114,239,056), within Exon 1 of a
TFDP1 long non-coding RNA (NR_026580.1). The 69 bp
fragment showed 100% sequence identity to a long
terminal repeat (LTR) of the endogenous retrovirus family
K (ERVK) located in Intron 3 of TFDP1. This LTR is 983
nt in length (Chr13:114,275,682-114,276,664). Collectively,Figure 2 Genomic rearrangement at 13q34. The 218,345 bp duplication
Browser (GRCH37/hg19 Assembly). The nucleotide sequence for the 69 bp
TFDP1, is shown in upper case red lettering.the complex structural variant identified in our patient
and her father can be denoted as NC_000013.10:
g.114,020,670_114,239,014dup218,345;g.114,239,014_11
4,239,015ins(A + 114,275,816_114,275,884). This variant
was also identified in one of the proband’s three brothers
(Table 3). It has not been reported in the Database of
Genomic Variants (http://projects.tcag.ca/variation/).
Relative gene expression in leukocytes is shown in
Table 4. In the affected subject and her father, relative
RNA expression was higher for all three genes located
within the duplication region (ADPRHL1, DCUN1D2
and TMCO3). However, in comparison to her mother
and neurologically normal controls, the affected subject
showed marked overexpression (>2×) of ADPRHL1 and
TMCO3. In contrast, gene expression in the father was
approximately 0.5× above control values for ADPRHL1,
DCUN1D2 and TMCO3, compatible with the presence
of three copies of these genes. Of particular note, TFDP1
and TFDP1 lncRNA showed strong leukocyte over-
expression in the affected subject but not in her father
or mother. For gene expression analyses, all assays
were performed in triplicate and means were used for
comparisons.
Exome sequencing and variant analysis
To identify other genetic factors that could cause or
contribute to risk of developing breast cancer and/or
dystonia, in-solution whole-exome capture and massively
parallel sequencing using the Agilent SureSelect XT All
Exon Kit 51 Mb (Santa Clara, CA, USA) was used to
examine the proband’s exome. Three micrograms of
genomic DNA from the subject was sheared to yield
100–450 bp fragments. Sheared DNA was then subjected
to Illumina paired-end library preparation followed by
enrichment for target sequences (Agilent SureSelectXT
Automated Target Enrichment for Illumina Paired-End
Multiplexed Sequencing). Enriched DNA fragmentsis shown beneath gene tracks adapted from the UCSC Genome
fragment, possibly duplicated from an LTR located in Intron 3 of
Table 2 Quantitative PCR of genomic DNA
Primers Location (13q34) Normal
controls
Subject fold change
NC_000013.10 (N = 9) Patient Father
(carrier)
Mother
Dup_018F/R 114018980-9123 1.00 ± 0.13 0.94 0.98 1.01
Dup_023F/R 114023386-3429 1.00 ± 0.15 1.47 1.51 0.99
Dup_025F/R 114025267-5677 1.00 ± 0.17 1.52 1.58 1.02
Dup_041F/R 114041257-1333 1.00 ± 0.12 1.57 1.49 0.98
Dup_228F/R 114228694-8793 1.00 ± 0.18 1.61 1.58 1.08
Dup_237F/R 114237214-7282 1.00 ± 0.09 1.53 1.55 1.02
Dup_241F/R 114241291-1364 1.00 ± 0.16 0.95 0.99 0.98
Dup_249F/R 114249685-9762 1.00 ± 0.10 1.10 1.04 1.01
Dup_257F/R 114257807-7900 1.00 ± 0.11 1.08 0.99 1.00
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paired-end 100 base reads (Otogenetics Co., Norcross,
GA, USA) and reads were mapped to the human refer-
ence genome with NextGENeW (SoftGenetics, State
College, PA, USA).
Over 99.7% of exons were covered at ≥2× and 97.6% of
exons were covered at ≥20×. To maximize the chances of
detecting a pathogenic variant, base changes occurring
in two or more reads were classified as variants for
downstream analyses. We focused on genes associated
with either breast cancer or dystonia (Additional file 2).
The pathogenicity of non-synonymous single amino
acid substitutions was interrogated with six in silico
tools: PolyPhen-2, MutationTaster, SIFTnew, LRTnew
(Likelihood Ratio Test), PhyloPnew, and ClustalW2 [21-23].
Sequence variants in SGCE, BRCA1, and XRCC3 were
confirmed by Sanger sequencing in the forward and re-
verse directions. We identified a novel variant in SGCE
(c.1295G > A, p.Ser432His) that is unlikely to be patho-










Father 71 Normal Yes c.1
c.1
Mother 70 Normal No c.1
Brother 47 Normal No c.1
Brother 46 Normal No c.1
Brother 43 Normal Yes c.1
c.1SIFT [24], p.Ser432His is poorly conserved [22] and classi-
fied as “benign” and “polymorphism” by Polyphen-2 [25]
and MutationTaster [26], respectively. Whole exome se-
quencing also identified a CIZ1 polymorphism that has
not been associated with dystonia. Polymorphisms
(dbSNP) were found in 16/25 breast cancer associated
genes (Additional file 2). Two of these (BRCA1, rs799917;
and XRCC3, rs861539) have shown potential but incon-
clusive associations with breast cancer [27,28].
Discussion
Dystonia is a neurological disorder characterized by invol-
untary sustained muscle contractions producing abnormal
postures, twisting and repetitive abnormal movements,
and sometimes painful muscle contractions. During
dystonic movements, agonist and antagonist muscles
co-contract in abnormal patterns. Dystonia is typically
classified into primary, secondary, heredodegenerative
diseases with dystonia, and dystonia-plus etiological
categories [29]. Mutations in TOR1A, THAP1, CIZ1,
ANO3, GNAL and TUBB4A have been associated with
some cases of primary dystonia [12,20,23,30-33]. However,
the genetic etiologies for most patients with primary
dystonia remain unknown. The dystonia-plus category
includes the myoclonus-dystonia syndrome (MDS) sec-
ondary to SGCE mutations. Nearly all affected individuals
have myoclonus and 50 to 65% manifest dystonia, typically
in the neck and arms. Depression and anxiety are import-
ant non-motor features of MDS. Although our proband
did harbor a potentially pathogenic SGCE missense vari-
ant, other carriers in the pedigree were asymptomatic.
Moreover, the anatomical distribution and onset age of
the proband’s dystonia were atypical for MDS.
Secondary dystonia is caused by exogenous factors
such as medications, toxins, or brain damage that may
result from head trauma and stroke. Drugs that block
dopamine receptors, such as neuroleptics and anti-
emetics, can cause acute dystonic reactions or late-onset,CE Exon10 BRCA1, rs799917 XRCC3, rs861539
NC_000017: NC_000014:
g.41244936G > A g.104165753G > A
294A > C (homozygous),
295G > A (heterozygous)
heterozygous heterozygous
294A > C (homozygous),
295G > A (heterozygous)
heterozygous wild-type
294A > C (homozygous) heterozygous heterozygous
294A > C (homozygous) heterozygous wild-type
294A > C (homozygous) heterozygous heterozygous
294A > C (homozygous),
295G > A (heterozygous)
heterozygous heterozygous











1.00 ± 0.18 2.71 1.70 1.10
ADPRHL1 P2 1.00 ± 0.25 2.26 1.70 1.10
DCUN1D2 P1 Within
duplication
1.00 ± 0.05 1.48 1.61 0.95
DCUN1D2 P2 1.00 ± 0.19 1.62 1.46 0.96
TMCO3 P1 Within
duplication
1.00 ± 0.13 3.13 1.68 1.04
TMCO3 P2 1.00 ± 0.06 2.69 1.59 1.21
TFDP1 P1 3' to
duplication
1.00 ± 0.20 1.95 1.05 1.25





1.00 ± 0.18 2.01 0.93 1.20
TFDP1
lncRNA P2
1.00 ± 0.21 2.15 0.95 1.11
GRTP1 P1 5' to
duplication
1.00 ± 0.13 1.08 0.89 1.26
GRTP1 P2 1.00 ± 0.10 0.98 0.85 1.28
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treatment [34]. Tardive movement disorders are usually
hyperkinetic and include classic tardive oral-buccal-lin-
gual dyskinesias and tardive chorea, dystonia, tics,
tremor and akathisia. The differentiation of tardive from
primary dystonia can be difficult and categorization
remains clinical as it was for our patient. In this regard,
it is quite uncommon for patients with tardive dystonia
to progressively worsen months after discontinuation of
drugs that block dopamine receptors. Although the
genetic susceptibility for developing tardive movement
disorders has been poorly characterized, sequence vari-
ants in genes associated with primary dystonia could be
risk factors [35,36]. For instance, a novel missense mu-
tation in TOR1A (c.613 T > A) has been linked to adult-
onset lower facial and masticatory, possibly tardive,
dystonia [35].
It is now well-established that GPi DBS exerts beneficial
effects on many dystonia subtypes [34-41]. In general,
current experience with DBS suggests that primary
dystonias respond better than most secondary dystonias
[42]. However, many reports indicate that tardive dystonia
can show significant improvements with DBS [42].
The complex structural variant identified in our patient
is of uncertain clinical significance since the three dupli-
cated genes have not been associated with dystonia, intel-
lectual disability or dysmorphism in human populations.
Moreover, two clinically unaffected family members
harbored the same variant. ADPRHL1 encodes an ADP-
ribosyltransferase that transfers ADP-ribose from NAD+
to target proteins. DCUN1D2 encodes a protein that maycontribute to neddylation of cullin components of SCF-
type E3 ubiquitin ligase complexes. Neddylation is the
process by which NEDD8 is conjugated to target pro-
teins. NEDD8 is an ubiquitin-like modifier of protein
function. Finally, TMCO3 encodes a transmembrane
protein that probably functions as a Na+/H+ antiporter.
Chromosome 13q34 has, however, been linked to can-
cer, and, in Chinese, harbors a quantitative trait locus
for physical height [43].
Pathogenic structural variants can be inherited from
normal parents [44-47]. Penetrance values have been
calculated for some of the more common structural vari-
ants and, for example, can range from 10.4% for 15q11.2
deletions to 62.4% for distal 16p11.2 deletions [47].
Some structural variants may be associated with several
phenotypes and penetrance is phenotype specific. Ultim-
ately, other genetic and environmental factors contribute
to penetrance and associated phenotypes. In the case of
our proband, neuroleptic exposure may have increased
her risk for breast cancer [48]. However, whole-exome
sequencing did not expose pathogenic non-structural
variants in genes associated with either breast cancer or
dystonia.
In our patient with dystonia and dysmorphism, it is
possible that the presence of the breakpoint within the
upstream promoter region of TFDP1 (NM_007111.4) is
responsible for altered expression of this transcription
factor. The breakpoint could abrogate the effects of 5′
repressor regions on TFDP1 expression. Over-expression
of the TFDP1 lncRNA could have also contributed to
this effect since some lncRNAs have been shown to play
important roles in transcriptional regulation [49]. In the-
ory, the consequences of the breakpoint on TFDP1
expression could be gender dependent. In this regard,
TFDP1 is part of the estrogen receptor ERα regulatory
network [50]. Epistasis and epigenetics (DNA methyla-
tion or histone deacetylation) are additional mechanistic
considerations [51] that could explain why the father
and brother are asymptomatic carriers of the structural
variant while the proband manifests dystonia due to
overexpression of TFDP1. Conversely, TFDP1 may have
played no causal role in our patient’s dystonia and other
clinical manifestations.
Conclusions
This is the first report to describe a potential connection
between TFDP1 and dystonia. Moreover, our analyses
suggest that a TFDP1 lncRNA (NR_026580.1) could play
a role in regulating TFDP1 expression. Our genetic find-
ings are compatible with numerous previous studies which
have consistently identified a link between chromosome
13q34 and cancer. Further studies in large case–control
cohorts will be needed to confirm possible associations
between chromosome 13q34 and dystonia.
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